Focus of the Report: This health technology assessment focuses on the use of an absorbable perirectal spacer (APS) (SpaceOAR; Boston Scientific) to prevent rectal toxicity in patients undergoing radiation therapy (RT) for prostate cancer (PCa).
Technology Description: The SpaceOAR APS is a polyethylene glycol hydrogel that is injected under anesthesia with transrectal ultrasound guidance into a space between the prostate and rectum. The APS is injected via dual syringes attached to a Y connector to allow for the 2 precursor agents to mix while being injected. The APS polymerizes into a solid spacer within 10 seconds following injection and is said to maintain its structure for 3 months before it starts to slowly hydrolyze and is cleared from the body via the kidneys, with only traces remaining by 6 months.
Controversy: The current standard care during RT for PCa is to conduct treatment without a spacer. Dose escalation in selected patients with PCa is well established, with improved local control, biochemical outcomes, and disease-free survival with doses above 70 grays (Gy). However, the location of the prostate gland in front of the rectum increases the potential vulnerability of this organ to clinically important complications from radiation toxicity and thus is a limiting factor in RT treatment protocols for PCa.
Is the SpaceOAR absorbable perirectal spacer (APS) effective in preventing rectal toxicity and improving quality of life (QOL) in patients with prostate cancer (PCa) undergoing radiation therapy (RT)?
How does the SpaceOAR APS compare with other rectal spacer devices or no spacer?
Is the SpaceOAR APS safe for use in patients with PCa undergoing RT?
Have definitive patient selection criteria been identified for use of the SpaceOAR in patients with PCa undergoing RT?
If you have a Hayes login, click here to view the full report on the Knowledge Center.